Soleus Capital Master Fund, L.P. 13D and 13G filings for VYNE Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 3:34 pm Sale |
2024-09-30 | 13G | VYNE Therapeutics Inc. VYNE |
Soleus Capital Master Fund, L.P. | 0 0.000% |
-703,868 (Position Closed) |
Filing |
| 2024-02-02 09:42 am Sale |
2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
Soleus Capital Master Fund, L.P. | 703,868 5.000% |
-187,000 (-20.99%) |
Filing |
| 2023-11-02 4:15 pm Purchase |
2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE |
Soleus Capital Master Fund, L.P. | 890,868 6.400% |
890,868 (New Position) |
Filing |